ASX ANNOUNCEMENT **20 MAY 2024**

CHM CDH17 PHASE 1/2 CLINICAL TRIAL APPROVED FOR INITIATION

Sydney, Australia, 20 May 2024: Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, is pleased to announce that it has received ethics approval for the initiation of the multi-site Phase 1/2 clinical trial of CHM CDH17 in patients with advanced gastrointestinal (GI) cancers.

Ethics approval represents a significant milestone in advancing the program toward study initiation under FDA regulations.

"We are excited to achieve this milestone in anticipation of opening our clinical trial of CHM CDH17 for patients with advanced GI cancers; this marks a great step forward for the use of cell therapies in solid tumours" said Dr Rebecca McQualter, Chief Operating Officer of Chimeric.

CHM CDH17 is a 3rd generation, novel CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumors including Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours.

The clinical program for CHM CDH17 builds upon the preclinical studies published in the preeminent scientific journal, Nature Cancer in March 2022 by leading immunotherapy scientist Xianxin Hua, MD, PhD, and his team at the Abramson Family Cancer Research Institute at the University of Pennsylvania. These experiments demonstrated that CHM CDH17 was able to eradicate established tumours in seven cancer models with no toxicity to normal tissues.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to

open additional clinical programs in 2024.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM CDH17 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer. CHM CDH17 is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours in 2024.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM CLTX is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CHM CORE-NK in combination regimens have been initiated. From the CHM CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors
Dr Rebecca McQualter
Chief Operating Officer
Chimeric Therapeutics
T: + 61 498 966 180
E: RMcQualter@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media
Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au